BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 15755586)

  • 21. Vaccine-elicited immune responses prevent clinical AIDS in SHIV(89.6P)-infected rhesus monkeys.
    Barouch DH; Fu TM; Montefiori DC; Lewis MG; Shiver JW; Letvin NL
    Immunol Lett; 2001 Nov; 79(1-2):57-61. PubMed ID: 11595290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques.
    Chong SY; Egan MA; Kutzler MA; Megati S; Masood A; Roopchard V; Garcia-Hand D; Montefiori DC; Quiroz J; Rosati M; Schadeck EB; Boyer JD; Pavlakis GN; Weiner DB; Sidhu M; Eldridge JH; Israel ZR
    Vaccine; 2007 Jun; 25(26):4967-82. PubMed ID: 17335943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SIV vaccine protection of rhesus monkeys.
    Gardner MB; Carlson JR; Jennings M; Rosenthal A; Langlois A; Haynes B; Bolognesi D; Palker TJ
    Biotechnol Ther; 1991; 2(1-2):9-19. PubMed ID: 1845125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV.
    Buckner C; Gines LG; Saunders CJ; Vojtech L; Srivastava I; Gettie A; Bohm R; Blanchard J; Barnett SW; Safrit JT; Stamatatos L
    Virology; 2004 Mar; 320(1):167-80. PubMed ID: 15003872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A genetically engineered live-attenuated simian-human immunodeficiency virus that co-expresses the RANTES gene improves the magnitude of cellular immunity in rhesus macaques.
    Shimizu Y; Inaba K; Kaneyasu K; Ibuki K; Himeno A; Okoba M; Goto Y; Hayami M; Miura T; Haga T
    Virology; 2007 Apr; 361(1):68-79. PubMed ID: 17157892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiprotein genetic vaccine in the SIV-Macaca animal model: a promising approach to generate sterilizing immunity to HIV infection.
    Maggiorella MT; Sernicola L; Crostarosa F; Belli R; Pavone-Cossut MR; Macchia I; Farcomeni S; Tenner-Racz K; Racz P; Ensoli B; Titti F
    J Med Primatol; 2007 Aug; 36(4-5):180-94. PubMed ID: 17669207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes.
    Chen X; Scala G; Quinto I; Liu W; Chun TW; Justement JS; Cohen OJ; vanCott TC; Iwanicki M; Lewis MG; Greenhouse J; Barry T; Venzon D; Fauci AS
    Nat Med; 2001 Nov; 7(11):1225-31. PubMed ID: 11689887
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel simian immunodeficiency virus CTL epitopes restricted by MHC class I molecule Mamu-B*01 are highly conserved for long term in DNA/MVA-vaccinated, SHIV-challenged rhesus macaques.
    Su J; Luscher MA; Xiong Y; Rustam T; Amara RR; Rakasz E; Robinson HL; MacDonald KS
    Int Immunol; 2005 May; 17(5):637-48. PubMed ID: 15824066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccine-induced, simian immunodeficiency virus-specific CD8+ T cells reduce virus replication but do not protect from simian immunodeficiency virus disease progression.
    Engram JC; Dunham RM; Makedonas G; Vanderford TH; Sumpter B; Klatt NR; Ratcliffe SJ; Garg S; Paiardini M; McQuoid M; Altman JD; Staprans SI; Betts MR; Garber DA; Feinberg MB; Silvestri G
    J Immunol; 2009 Jul; 183(1):706-17. PubMed ID: 19542473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity of a DNA prime and recombinant adenovirus boost regime significantly varies between rhesus macaques of Chinese and Indian origins.
    Stahl-Hennig C; Suh YS; Park KS; Sauermann U; Kim KS; Ahn S; Franz M; Schulte R; Stolte-Leeb N; Hunsmann G; Sung YC
    J Med Primatol; 2007 Aug; 36(4-5):195-205. PubMed ID: 17669208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges.
    Ellenberger D; Otten RA; Li B; Aidoo M; Rodriguez IV; Sariol CA; Martinez M; Monsour M; Wyatt L; Hudgens MG; Kraiselburd E; Moss B; Robinson H; Folks T; Butera S
    Virology; 2006 Aug; 352(1):216-25. PubMed ID: 16725169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving the sensitivity of the ELISPOT analyses of antigen-specific cellular immune responses in rhesus macaques.
    Sastry KJ; Nehete PN; Nehete B
    Methods Mol Biol; 2005; 302():153-66. PubMed ID: 15937350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chimeric adenovirus type 5/35 vector encoding SIV gag and HIV env genes affords protective immunity against the simian/human immunodeficiency virus in monkeys.
    Someya K; Xin KQ; Ami Y; Izumi Y; Mizuguchi H; Ohta S; Yamamoto N; Honda M; Okuda K
    Virology; 2007 Oct; 367(2):390-7. PubMed ID: 17628628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy for AIDS virus infections: cautious optimism for cell-based vaccine.
    Bhardwaj N; Walker BD
    Nat Med; 2003 Jan; 9(1):13-4. PubMed ID: 12514710
    [No Abstract]   [Full Text] [Related]  

  • 35. Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge.
    Bogers WM; Davis D; Baak I; Kan E; Hofman S; Sun Y; Mortier D; Lian Y; Oostermeijer H; Fagrouch Z; Dubbes R; van der Maas M; Mooij P; Koopman G; Verschoor E; Langedijk JP; Zhao J; Brocca-Cofano E; Robert-Guroff M; Srivastava I; Barnett S; Heeney JL
    Virology; 2008 Dec; 382(2):217-25. PubMed ID: 18947849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A dendritic cell-based vaccine for treating HIV infection: background and preliminary results.
    Andrieu JM; Lu W
    J Intern Med; 2007 Feb; 261(2):123-31. PubMed ID: 17241177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Involvement of multiple epitope-specific cytotoxic T-lymphocyte responses in vaccine-based control of simian immunodeficiency virus replication in rhesus macaques.
    Kawada M; Igarashi H; Takeda A; Tsukamoto T; Yamamoto H; Dohki S; Takiguchi M; Matano T
    J Virol; 2006 Feb; 80(4):1949-58. PubMed ID: 16439550
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CTL ontogeny and viral escape: implications for HIV-1 vaccine design.
    Yang OO
    Trends Immunol; 2004 Mar; 25(3):138-42. PubMed ID: 15036041
    [No Abstract]   [Full Text] [Related]  

  • 39. Evaluation of recombinant Kunjin replicon SIV vaccines for protective efficacy in macaques.
    Kent SJ; De Rose R; Mokhonov VV; Mokhonova EI; Fernandez CS; Alcantara S; Rollman E; Mason RD; Loh L; Peut V; Reece JC; Wang XJ; Wilson KM; Suhrbier A; Khromykh A
    Virology; 2008 May; 374(2):528-34. PubMed ID: 18272194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infection.
    Mooij P; van der Kolk M; Bogers WM; ten Haaft PJ; Van Der Meide P; Almond N; Stott J; Deschamps M; Labbe D; Momin P; Voss G; Von Hoegen P; Bruck C; Heeney JL
    AIDS; 1998 Mar; 12(5):F15-22. PubMed ID: 9543435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.